Cargando…

Fluvastatin-Pretreated Donor Cells Attenuated Murine aGVHD by Balancing Effector T Cell Distribution and Function under the Regulation of KLF2

Prevention of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still to be explored. Statins are potent immunomodulatory agents that hold promise as novel and safe agents for aGVHD prophylaxis, yet the controversial effect and regulatory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Kai, Tian, Yu, Wang, Junjie, Chen, Chong, Pan, Bin, Yan, Zhiling, Zhu, Shengyun, Xu, Kailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769635/ https://www.ncbi.nlm.nih.gov/pubmed/33415155 http://dx.doi.org/10.1155/2020/7619849

Ejemplares similares

Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells
por: Gao, Ya, et al.
Publicado: (2021)

Tyrosine supplement ameliorates murine aGVHD by modulation of gut microbiome and metabolome
por: Li, Xiaoqing, et al.
Publicado: (2020)

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
por: Song, Yuan, et al.
Publicado: (2020)

Intestinal aGVHD and infection after hematopoietic stem cell transplantation
por: Hou, Cai-yan, et al.
Publicado: (2013)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

The Potential Genes Mediate the Pathogenicity of Allogeneic CD4(+)T Cell in aGVHD Mouse Model
por: Yu, Zhengyu, et al.
Publicado: (2021)

Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies
por: Naserian, Sina, et al.
Publicado: (2020)

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD
por: He, Fiona, et al.
Publicado: (2016)

Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)
por: Efebera, Yvonne A, et al.
Publicado: (2019)

Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice
por: Dorrance, Adrienne M., et al.
Publicado: (2022)

Compound A Increases Cell Infiltration in Target Organs of Acute Graft-versus-Host Disease (aGVHD) in a Mouse Model
por: Bouazzaoui, Abdellatif, et al.
Publicado: (2021)

Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials
por: Luo, Chengxin, et al.
Publicado: (2023)

Three-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept study
por: Han, Hongxing, et al.
Publicado: (2015)

Adipose tissue-derived stem cells modulate immune function in vivo and promote long-term hematopoiesis in vitro using the aGVHD model
por: Jiang, Ming, et al.
Publicado: (2020)

Human Amniotic Mesenchymal Stem Cells Alleviate aGVHD after allo-HSCT by Regulating Interactions between Gut Microbiota and Intestinal Immunity
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021)

Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells
por: Riegel, Christin, et al.
Publicado: (2019)

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
por: Zhu, Jinye, et al.
Publicado: (2023)

HMGB1 Recruits TET2/AID/TDG to Induce DNA Demethylation in STAT3 Promoter in CD4(+) T Cells from aGVHD Patients
por: Xu, Xuejun, et al.
Publicado: (2020)

Tumor necrosis factor α in aGVHD patients contributed to the impairment of recipient bone marrow MSC stemness and deficiency of their hematopoiesis-promotion capacity
por: Ding, Li, et al.
Publicado: (2020)

Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition
por: Zhao, Yanna, et al.
Publicado: (2022)

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion
por: Qi, Ling, et al.
Publicado: (2021)

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Enhanced alleviation of aGVHD by TGF‐β1‐modified mesenchymal stem cells in mice through shifting MΦ into M2 phenotype and promoting the differentiation of Treg cells
por: Wu, Ran, et al.
Publicado: (2019)

Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage
por: He, Xin, et al.
Publicado: (2016)

Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin
por: Wuestenberg, Andrea, et al.
Publicado: (2014)

Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin
por: Lee, Chong-Ki, et al.
Publicado: (2013)

Enantiospecific Pharmacogenomics of Fluvastatin
por: Hirvensalo, Päivi, et al.
Publicado: (2019)

CrkL is required for donor T cell migration to GvHD target organs
por: Roy, Nathan H., et al.
Publicado: (2020)

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group
por: El Jurdi, Najla, et al.
Publicado: (2021)

The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects
por: Xu, H. R., et al.
Publicado: (2012)

PB2405: BAICALIN MODULATES INTESTINAL FLORA TO TREAT AGVHD
por: Yang, Jingrong, et al.
Publicado: (2023)

Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
por: Okubo, Kazuki, et al.
Publicado: (2019)

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
por: Holtan, Shernan G., et al.
Publicado: (2023)

Regulatory T Cells in GVHD Therapy
por: Guo, Wen-wen, et al.
Publicado: (2021)

Kinetic Spectrophotometric Determination of Fluvastatin in Pharmaceutical Preparations
por: Ashour, Safwan, et al.
Publicado: (2010)

Donor Bone Marrow-Derived T Cells Inhibit GVHD Induced by Donor Lymphocyte Infusion in Established Mixed Allogeneic Hematopoietic Chimeras
por: Wang, Hui, et al.
Publicado: (2012)

Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation
por: Lv, Meng, et al.
Publicado: (2013)

Donor‐derived M2 macrophages attenuate GVHD after allogeneic hematopoietic stem cell transplantation
por: Hanaki, Ryo, et al.
Publicado: (2021)

Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
por: Zapatero-Belinchón, Francisco J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7hk30qhg35qd55157fb0obmjai